[与年龄相关的黄斑变性 - 第二部分:AMD的治疗选择]
概括
静脉内抗VEGF疗法对新血管性AMD至关重要,新药和生物类似药改善了治疗持续时间和患者的坚持. 补充抑制剂通过减缓生长来减缓地理缩有希望,尽管视觉功能的好处需要进一步研究.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 内抗VEGF治疗是当前在新血管AMD中维持功能的标准.
- 形态生物标志物,如内液和下液,指导治疗决策.
- 新的抗VEGF药物,双特异性抗体和生物仿制药旨在延长治疗时间并减少患者的负担.
研究的目的:
- 审查新血管AMD和地理缩的当前和新兴疗法.
- 讨论治疗持续时间和坚持治疗的影响.
- 评估内补充抑制剂对地理缩的疗效.
主要方法:
- 重点试验的审查和补充研究的特设分析 (AREDS,AREDS2).
- 分析已批准的疗法和新兴的治疗策略.
- 对形态生物标志物的检查,以提供治疗指导.
主要成果:
- 较高的度和双特异性抗体延长了抗VEGF的作用,可能改善了粘附性.
- 贝瓦西祖马布已在欧洲批准用于新血管AMD.
- 内补充抑制剂在研究中减缓了地理缩的增长,但视觉功能与对照组没有差异.
- 补充研究表明,在某些干预措施下,RPE缩的进展较慢.
结论:
- 抗VEGF治疗的进步为新血管AMD提供了更好的结果和坚持.
- 补充抑制剂显示出减缓地理缩的潜力,但视觉效益需要确认.
- 进一步的随机试验是必要的,以验证地理缩治疗的发现.
更多相关视频
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
2.0K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
987
相关概念视频
iPS Cell Differentiation
2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
Open Angle Glaucoma: Treatment
375
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
375
